SCHEMBL816422

SCHEMBL816422

COC(=O)CCCCCCO

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.67
LMNA P02545 2/20 0.57
ALDH1A1 P00352 1/20 0.57
GPR84 Q9NQS5 1/20 0.50
FFAR1 O14842 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RECQL P46063 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 1/20 0.44
FNTA P49354 1/20 0.43
FNTB P49356 1/20 0.43
EPHX2 P34913 2/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.42
POLA1 P09884 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4758469 1.00 TSHR (0.67) TSHRLMNAALDH1A1GPR84FFAR1
SCHEMBL4757158 1.00 TSHR (0.67) TSHRLMNAALDH1A1GPR84FFAR1
SCHEMBL1277943 1.00 TSHR (0.67) TSHRLMNAALDH1A1GPR84FFAR1
SCHEMBL4758137 1.00 TSHR (0.67) TSHRLMNAALDH1A1GPR84FFAR1
SCHEMBL1199597 1.00 TSHR (0.67) TSHRLMNAALDH1A1GPR84FFAR1
SCHEMBL1976107 1.00 TSHR (0.67) TSHRLMNAALDH1A1GPR84FFAR1
SCHEMBL1886420 1.00 TSHR (0.67) TSHRLMNAALDH1A1GPR84FFAR1
SCHEMBL1245383 1.00 TSHR (0.67) TSHRLMNAALDH1A1GPR84FFAR1
SCHEMBL2235775 1.00 TSHR (0.67) TSHRLMNAALDH1A1GPR84FFAR1
SCHEMBL4758409 1.00 TSHR (0.67) TSHRLMNAALDH1A1GPR84FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180002729-A1 METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS INVISTA NORTH AMERICA S.A.R.L. 2018-01-04 US claimed
CN-106795537-A Methods, reagents and cells for biosynthesis of compounds 英威达技术有限责任公司 2017-05-31 CN claimed
EP-3155109-A1 METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS Invista Technologies S.A R.L. (CH) 2017-04-19 EP claimed
WO-2015195678-A1 METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS INVISTA TECHNOLOGIES S.À R.L. (CH) 2015-12-23 WO claimed
US-20150361465-A1 METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS INV NYLON CHEMICALS AMERICAS, LLC 2015-12-17 US claimed
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 EP disclosed
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 US disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 WO disclosed
CN-115141123-B Compound, preparation method thereof and application thereof in preparation of dual inhibitors of histone deacetylase and epoxide hydrolase 沈阳药科大学 2024-05-17 CN disclosed
CN-117865991-A Preparation and application of biotin-coupled dihydroartemisinin 成都理工大学 2024-04-12 CN disclosed
CN-113387938-B Substituted pyrimidine compound, preparation method, intermediate and application thereof 上海科技大学 2023-08-18 CN disclosed
CN-110959009-B Method for introducing substituent to alpha, beta-unsaturated ketone and method for synthesizing prostanoid using the same 国立研究开发法人国立长寿医疗研究中心 2023-02-28 CN disclosed
WO-1997001543-A1 1-AMINO-3-BENZYLURACILS BASF AKTIENGESELLSCHAFT (DE) 1997-01-16 WO disclosed
US-5457205-A Substituted thiazoles useful for treatment of diabetes DR. KARL THOMAE GMBH (DE) 1995-10-10 US disclosed
US-RE34722-E Antiulcer agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-09-06 US disclosed
US-5219852-A Hypoglycemic agents, treatment of diabetes and obesity DR. KARL THOMAE GMBH (DE) 1993-06-15 US disclosed
US-5026702-A Enhances physical performance in animals, effective in lowering blood sugar, reducing body fat and lowering atherogenic lipoproteins DR. KARL THOMAE, GMBH (DE) 1991-06-25 US disclosed
US-4886814-A LOWER BLOOD SUGAR DR. KARL THOMAS GMBH (DE) 1989-12-12 US disclosed
US-4859799-A Process for the production of aldehyde or ketone compounds and aldehydes and ketones obtained by means of this process INTEROX (SOCIETE ANONYME) (BE) 1989-08-22 US disclosed
US-4578381-A ANTIULCER AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361465-A1 METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS PNMT, HNMT, ACOT7 TSHR 2112/4885LMNA 3733/4885ALDH1A1 302/4885
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF SIGLEC7, SIGLEC9, CD2BP2 TSHR 1160/4885LMNA 2421/4885ALDH1A1 802/4885
US-20180002729-A1 METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS PNMT, HNMT, ACOT7 TSHR 2112/4885LMNA 3733/4885ALDH1A1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.